
Merck & Co. MRK
Quarterly report 2025-Q3
added 11-05-2025
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.53 B |
Market Cap[1] |
$ 296 B |
EBITDA (LTM) |
$ 2.86 B |
P/E (LTM) |
15.97 |
P/S (LTM) |
4.55 |
EPS (LTM) |
7.34 |
Merck & Co., Inc. is a global pharmaceutical company that specializes in the development, manufacturing, and distribution of innovative medicines, vaccines, and animal health products. Founded in 1891, Merck has grown to become one of the largest pharmaceutical companies in the world, with operations in over 140 countries.
The company's mission is to improve the health and well-being of people and animals around the world. Merck is committed to discovering new treatments and cures for some of the most challenging diseases, including cancer, Alzheimer's disease, and HIV/AIDS. The company has a strong pipeline of products in development, with a focus on immunotherapy and oncology.
Merck is also a leader in the development and distribution of vaccines. The company has played a key role in the fight against infectious diseases such as measles, mumps, rubella, and HPV. Merck's vaccines have saved countless lives around the world and continue to be an important tool in preventing disease outbreaks.
In addition to its pharmaceutical and vaccine business, Merck also has a thriving animal health division. The company develops and manufactures products for livestock, pets, and wildlife. Merck's animal health products are used to prevent and treat diseases in animals, improving their health and welfare.
Merck is committed to operating responsibly and sustainably. The company has set ambitious goals to reduce its environmental impact, improve the health and safety of its employees, and support the communities where it operates. Merck has been recognized for its sustainability efforts, including being named to the Dow Jones Sustainability Index for the past 16 years.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Akebia Therapeutics
AKBA
|
$ 1.48 | -1.67 % | $ 277 M | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Amarin Corporation plc
AMRN
|
$ 14.7 | -0.34 % | $ 5.99 B | Nasdaq Global Market | ||
|
ANI Pharmaceuticals
ANIP
|
$ 79.9 | -0.55 % | $ 1.54 B | Nasdaq Global Market,SPB | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Aptorum Group Limited
APM
|
$ 0.88 | 5.24 % | $ 4.8 M | Nasdaq Global Select Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Adagene
ADAG
|
$ 2.66 | -0.37 % | $ 150 M | Nasdaq Global Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.5 | -2.1 % | $ 8.42 B | Nasdaq Capital Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
BioNTech SE
BNTX
|
$ 110.96 | 0.56 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Cabaletta Bio
CABA
|
$ 2.48 | 1.64 % | $ 2.9 M | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Compugen Ltd.
CGEN
|
$ 1.75 | 2.05 % | $ 157 M | Nasdaq Global Market,SPB | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Ascendis Pharma A/S
ASND
|
$ 220.07 | -0.88 % | $ 5 B | Nasdaq Global Select Market | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 41.12 | -0.46 % | $ 4.24 B | Nasdaq Capital Market,SPB | ||
|
Burford Capital Limited
BUR
|
$ 9.23 | 2.9 % | $ 1.44 B | NYSE | ||
|
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
Catalyst Pharmaceuticals
CPRX
|
$ 24.29 | -0.67 % | $ 2.88 B | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 49.94 | 0.48 % | $ 4.21 B | Nasdaq Global Market,SPB | ||
|
Champions Oncology
CSBR
|
$ 6.54 | -0.15 % | $ 89.3 M | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 4.45 | 5.33 % | $ 9.68 B | NYSE American | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.46 | - | $ 373 M | Nasdaq Global Select Market | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 14.48 | -0.28 % | $ 4.47 B | NYSE |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.